FutureGen Industries Announces Closing of Debt Settlement

VANCOUVER, BC / ACCESS Newswire / March 26, 2026 / FutureGen Industries Corp. (formerly Right Season Investments Corp.) (TSXV:LITT)(Frankfurt:T500, WKN: A41WY4) ("FutureGen Industries" or the "Company") announces that it has closed its previously announced debt settlement agreement with a director of the Company (the "Creditor") dated March 9, 2026 (the "Settlement Agreement"). Pursuant to the Settlement Agreement, the Company has issued to the Creditor 100,800 common shares of the Company (each, a "Share" and, collectively, the "Shares") at a deemed price of $0.25 per Share in settlement of $25,200 of outstanding indebtedness (the "Settlement"). Pursuant to applicable securities laws, all securities issued pursuant to Settlement are subject to a hold period of four months and one day, expiring July 27, 2026.

The issuance of 100,800 Shares to Constantine Carmichel, in full settlement of $25,200 is considered a Related Party Transactions within the meaning of Multilateral Instrument 61-101 - Protection of Minority Security Holdings in Special Transactions ("MI 61-101"). The Company relied on exemptions from the formal valuation and minority approval requirements of MI 61-101 contained in sections 5.5(a) and 5.7(1)(a) of MI 61-101, as neither the fair market value of the Shares, nor the consideration paid for the Shares, exceeded 25% of the Company's market capitalization.

The Company did not file a material change report more than 21 days before the closing of the Settlement because the details were not settled until shortly prior to closing and the Company wished to complete the Settlement on an expedited basis for business reasons.

About FutureGen Industries Corp.

FutureGen Industries Corp. is a Canadian venture capital, investment and advisory firm that strives to actively drive innovation and accelerate growth for its shareholders. FutureGen invests capital into private and public companies that offer excellent growth opportunities.

Contact:

Kristian Thorlund, CEO
Tel: 1 833 383 9900
Email: investor@futuregenindustries.com

Cautionary and Forward-Looking Statements

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this release.

This news release contains "forward-looking information" within the meaning of applicable securities laws, including statements regarding the issuance of the Shares and obtaining regulatory approvals. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, that the Company's plans and prospects will vary from those stated in this news release and that the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Accordingly, readers should not place undue reliance on forward-looking information. The statements in this news release are made as of the date of this release.

SOURCE: FutureGen Industries



View the original press release on ACCESS Newswire

News Provided by ACCESS Newswire via QuoteMedia

LITT:CC
The Conversation (0)
Dried mushrooms in the center are surrounded by translucent capsules on a white background.

Executive Order Sparks New Phase for Psychedelic Biotech, Risks Remain

On April 18, President Trump was joined by top health officials in the Oval Office to sign Accelerating Medical Treatments For Serious Mental Illness, an executive order to expand research into ibogaine. This signals the strongest federal endorsement yet of psychedelic medicine as an alternative... Keep Reading...
Numinus Wellness Responds to Trump Executive Order on Psychedelic Therapies

Numinus Wellness Responds to Trump Executive Order on Psychedelic Therapies

Company's clinical research operations and therapist training programs directly positioned to support accelerated research and commercialization timelinesNuminus Wellness Inc. (OTC: NUMIF) today acknowledged the Executive Order signed by President Donald J. Trump directing United States federal... Keep Reading...
Emyria Limited

Emyria Launches Global Services Platform Targeting International Drug Sponsors

Emyria’s established, world-first, unique national clinical delivery network to drive a new services-led revenue stream focused on global drug sponsors.

Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”), a leader in innovative mental health treatments, is pleased to announce the launch of its Empax Global Partnership Program, a new services platform enabling international drug sponsors to access Emyria’s established clinical delivery... Keep Reading...
Numinus Wellness Provides Update Regarding Listing Status

Numinus Wellness Provides Update Regarding Listing Status

Numinus Wellness Inc. (TSX: NUMI) (OTC Pink: NUMIF) ("Numinus" or the "Company"), a mental health care company focused on innovative behavioral health treatments with an emphasis on safe, evidence-based psychedelic-assisted therapies, is providing an update regarding its listing status on the... Keep Reading...
Numinus Wellness Provides Corporate Update

Numinus Wellness Provides Corporate Update

Numinus Wellness Inc. (TSX: NUMI) (OTC: NUMIF) ("Numinus" or the "Company"), a mental health care company focused on innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, is providing a corporate update.Corporate UpdateOver the past year,... Keep Reading...
Numinus Wellness Advises of a Change of Auditor

Numinus Wellness Advises of a Change of Auditor

Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) ("Numinus" or the "Company"), a mental health care company focused on innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, is advising of a change of its auditor. The Company's previous... Keep Reading...

Interactive Chart

Latest Press Releases

Related News